Business Context and Reporting Period
Company: VERACYTE, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: July 25, 2018
Event: Entry into a Material Definitive Agreement for a public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Specific figures include:
- Shares Offered: 5,000,000 shares of common stock.
- Offering Price: $10.25 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to 750,000 additional shares within 30 days.
- Estimated Net Proceeds: Approximately $47.9 million (after underwriting discounts, commissions, and estimated expenses, assuming no exercise of the option).
- Use of Proceeds: Working capital, general corporate purposes, and potential acquisition of complementary businesses or technologies (no current commitments).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an underwriting agreement with Leerink Partners LLC and William Blair & Company L.L.C. to raise capital. The offering is expected to close on or about July 30, 2018, subject to customary closing conditions.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use net proceeds for working capital and general corporate purposes. While the Company may use a portion of the proceeds for acquisitions or investments, it explicitly states it has no present commitments or agreements to do so.
Risks/Contingencies: The closing of the offering is subject to customary closing conditions. The description of the Underwriting Agreement is qualified by reference to the full text filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the final closing date of the offering (expected July 30, 2018).
- Confirm whether the underwriters exercise the 750,000 share over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific terms and conditions.
- Monitor future filings for the actual use of proceeds, particularly regarding any potential acquisitions.